The global interventional oncology market is experiencing significant growth, driven by the rising global cancer burden, increasing adoption of minimally invasive procedures, and continuous advancements in image-guided cancer treatment. Interventional oncology combines imaging technologies with targeted procedures to diagnose and treat tumors while minimizing damage to surrounding healthy tissues. Techniques such as tumor ablation, embolization, and image-guided biopsy are becoming increasingly important in modern cancer care, creating new opportunities for medical device manufacturers and healthcare providers. 

Download a free sample copy of the Interventional Oncology Market report to understand detailed coverage and inclusions in the final report 

Market Size & Growth Forecast

The interventional oncology market is expected to maintain a strong growth trajectory as hospitals and specialty clinics expand their capabilities in minimally invasive cancer treatment.

• Market size in 2025: USD 2.9 billion.

• Estimated market size in 2026: USD 3.2 billion.

• Projected market size by 2033: USD 5.6 billion.

• CAGR from 2026 to 2033: 8.6%.

• Largest regional market: North America, with a 41.8% revenue share in 2025.

These projections reflect the increasing role of image-guided interventions in cancer care. Demand is expected to benefit from advances in tumor ablation, embolization technologies, and diagnostic procedures. The pace of adoption will also depend on reimbursement policies, clinical outcomes, healthcare spending, and the availability of trained specialists.

Core Market Segmentation

The global interventional oncology market is segmented by technique, procedure, application, end use, and region. These categories represent different treatment approaches, clinical requirements, and healthcare delivery settings.

By Technique

The ablation therapies segment held the largest market share in 2025. Ablation procedures destroy targeted tumor tissue using controlled energy or extreme temperatures, offering a minimally invasive option for selected solid tumors. 

• Ablation therapies: Include radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, laser ablation, and irreversible electroporation (IRE). The tumor ablation segment is projected to grow at a CAGR of 9.1% during the forecast period, supported by increasing adoption of minimally invasive tumor treatment. 

• Embolization therapies: Include transarterial chemoembolization (TACE) and transarterial radioembolization (TARE). These procedures deliver therapeutic agents or radioactive materials through blood vessels supplying a tumor.

• Biopsy techniques: Include core needle biopsy and fine needle aspiration, which help obtain tissue or cellular samples for diagnostic evaluation.

• Targeted therapy delivery systems: Include drug-eluting beads and other technologies designed to deliver treatments to specific locations.

Advances in ablation equipment and embolization materials are helping expand the range of tumors that can be treated using image-guided procedures. Clinical suitability continues to depend on tumor characteristics, disease stage, and individual patient factors.

By Procedure

The vascular interventions segment accounted for 38.1% of market revenue in 2025, making it the leading procedure category. These procedures use catheter-based techniques to access blood vessels and deliver treatments to targeted areas. 

• Vascular interventions: Include catheter-guided procedures used to treat tumors through targeted embolization and localized delivery of therapeutic agents.

• Tumor ablation: Uses thermal or nonthermal energy to destroy tumor tissue while limiting damage to nearby structures.

• Tumor biopsy: Supports cancer diagnosis by obtaining tissue samples for laboratory analysis.

• Palliative care: Includes interventional procedures intended to relieve symptoms and improve quality of life in patients with cancer.

The tumor ablation segment is expected to grow rapidly as treatment technologies improve and clinicians gain access to more precise image-guided systems. Vascular interventions remain important because they can deliver localized therapies to tumors supplied by specific blood vessels.

By Application

The liver cancer segment held the largest application share at 27.8% in 2025. Interventional oncology plays an important role in the management of selected liver tumors through ablation and embolization procedures. 

• Liver cancer: Benefits from established interventional approaches, including TACE, TARE, and image-guided tumor ablation.

• Lung cancer: Represents an important application for image-guided ablation in selected patients, particularly when localized treatment is appropriate.

• Kidney cancer: May be treated with minimally invasive ablation techniques in eligible patients.

• Prostate cancer: Offers opportunities for targeted procedures as image-guided treatment technologies develop.

• Breast and other cancers: Represent additional applications where selected interventional techniques may complement established treatment approaches.

The lung cancer segment is projected to grow at a CAGR of 9.4% from 2026 to 2033, reflecting expanding applications for image-guided treatment. 

By End Use

The hospitals segment accounted for 55.3% of market revenue in 2025, establishing hospitals as the leading end-use category. Hospitals have the imaging infrastructure, specialist teams, and procedural facilities needed to perform complex interventional oncology treatments. 

• Hospitals: Benefit from established oncology departments, advanced imaging systems, and multidisciplinary cancer treatment teams.

• Specialty clinics: Are expected to experience the fastest growth as dedicated providers expand specialized cancer care and minimally invasive services.

The growth of specialty clinics reflects increasing interest in focused treatment services and patient-centered care. However, the availability of suitable equipment, trained clinicians, and reimbursement remains important to the expansion of both end-user segments.

Regional Market Insights

North America dominated the global interventional oncology market with a 41.8% revenue share in 2025, supported by advanced healthcare infrastructure, substantial healthcare expenditure, and the presence of established medical technology companies. 

North America benefits from established cancer treatment centers, advanced imaging technologies, and access to specialized medical professionals. Continued investment in minimally invasive procedures is supporting demand for ablation and embolization devices.

Europe is supported by established healthcare systems and increasing adoption of advanced medical technologies. Hospitals and specialist centers are incorporating image-guided procedures into multidisciplinary treatment pathways where clinically appropriate.

Asia Pacific offers substantial growth opportunities because of its large patient population, rising cancer incidence, and expanding healthcare infrastructure. Investments in diagnostic facilities and specialized treatment services are expected to improve access to interventional oncology procedures.

Latin America and the Middle East & Africa present opportunities for market expansion as healthcare providers invest in modern imaging systems and cancer treatment infrastructure. However, equipment affordability, specialist availability, and access to advanced care remain important considerations.

Key Market Trends & Drivers

Growing Preference for Minimally Invasive Procedures

The shift toward minimally invasive cancer treatments is a major market driver. Image-guided interventions can provide targeted treatment while reducing the need for large surgical incisions in appropriate cases. Depending on the procedure and clinical circumstances, these approaches may also reduce recovery time and hospital stays.

Technological Advancements and Image Guidance

Advances in CT, ultrasound, fluoroscopy, and other imaging technologies are improving the precision of interventional procedures. Innovations in ablation systems, catheters, embolic materials, and treatment-planning software are expanding the capabilities of clinicians.

Artificial intelligence is also being explored for image analysis, treatment planning, and procedural guidance. These applications could help clinicians interpret complex imaging data and improve workflow efficiency, although clinical effectiveness depends on the specific technology and use case.

Rising Global Cancer Burden

The increasing number of cancer cases is driving demand for additional treatment options. Interventional oncology can complement surgery, systemic therapies, and radiation treatment in selected clinical situations. Its use across multiple tumor types provides opportunities for continued development.

Combination Treatment Approaches

Multidisciplinary cancer care is creating opportunities to combine localized interventional procedures with systemic treatments, including immunotherapy, when supported by clinical evidence. These approaches aim to improve disease control and tailor treatment to individual patient needs.

Market Challenges

High equipment acquisition costs, expensive specialized consumables, and the need for trained interventional radiologists can restrict adoption. Healthcare facilities must also invest in imaging infrastructure, procedural support, and ongoing staff training.

Differences in reimbursement and access to specialized cancer services may further limit market penetration in developing regions. Addressing these barriers will be important to ensuring broader access to advanced interventional oncology procedures.

Looking for more specific insights? Customize this report to suite your business needs

Major Competitors and Industry Landscape

The interventional oncology market includes medical device manufacturers and healthcare technology companies competing through product innovation, clinical performance, and expanded procedural capabilities.

Key companies identified by Grand View Research include:

• Medtronic plc

• Boston Scientific Corporation

• Johnson & Johnson (Ethicon)

• Cook Medical

• AngioDynamics, Inc.

• Stryker Corporation

• Terumo Corporation

• Siemens Healthineers

• GE HealthCare

• Teleflex Incorporated

• Profound Medical

These companies operate across areas such as ablation systems, embolization technologies, image-guided treatment equipment, and catheter-based devices. Product development, strategic acquisitions, clinical collaborations, and geographic expansion are important competitive strategies.

About us:

Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.

Explore U.S. Healthcare Facility Mapping & Intelligence Platform - https://www.grandviewresearch.com/horizon/hospital-database